Treatment of Haemophilus bacteremia with benzylpenicillin is associated with increased (30-day) mortality

BMC Infectious Diseases

Christian Østergaard¹  Sara Thønnings¹ 

[1] Department of Clinical Microbiology, Copenhagen University Hospital Hvidovre, Kettegård Alle 30, Hvidovre, DK-2650, Denmark

关键词: Charlson comorbidity index;    Acquisition;    Antibiotic therapy;    Mortality;    Bacteremia;    Haemophilus;   

Others  :  1175338
DOI  :  10.1186/1471-2334-12-153

 received in 2011-12-30, accepted in 2012-07-09,  发布年份 2012

【 摘 要 】

Background

Optimal antibiotic treatment strategies of Haemophilus infections are still needed. Therefore, 30-day case fatality rate (CFR) of Haemophilus bacteremia and efficacy of various antibiotic treatment regimes were studied.

Methods

All episodes of Haemophilus bacteremia in the former Copenhagen County during the period 2000-9 were included in the study. Clinical and biochemical findings and outcome were collected retrospectively from medical records.

Results

105 consecutive episodes were identified (median age: 69 years, with only 4 children <16 years), 72% were due to non-typeable -, 16% to typeable H. influenzae, and 11% to other Haemophilus species. Pneumonia was the most common primary focus (in 48%), and 58% of the patients had Charlson comorbidity index > 1. Definitive antibiotic therapy was in 26 cases benzylpenicillin, in 12 cases aminopenicillins, in 50 cases cefuroxime and in 16 cases broadspectrum antibiotics, whereas 1 palliative case died without start of therapy. Whereas the use of broadspectrum antibiotics was related to the severity of the disease (admittance to ICU, need for assisted ventilation or hemodialysis, septic shock), no significant difference in clinical features was demonstrated for therapy with benzylpenicillin, aminopenicillin or cefuroxime, except benzylpenicillin was rarely administered to immunosuppressed patients. The CFR was 22% (23/105). The choice of empiric antibiotic therapy was not significantly associated with mortality (adequate vs. inadequate treatment: 23% (21/93) vs. 17% (2/12), respectively, P > 0.05). In contrast, definite antibiotic therapy with cefuroxime or aminopenicillins resulted in a significantly lower CFR than treatment with benzylpenicillin (12% (6/50) or 0% (0/12) vs. 39% (10/26), respectively, Log rank test P < 0.02). When adjustments were made for other identified risk factors in bivariate logistic regression analysis, treatment with cefuroxime was still were found to be associated with a significantly lower CFR than for benzylpenicillin: OR: 0.21 (0.06-0.69), P = 0.01 (hospital-acquired bacteremia), OR: 0.27 (0.08-0.91), P = 0.04 (polymicrobial episodes), OR: 0.16 (0.04-0.59), P = 0.006 (admittance at intensive care unit), OR: 0.22 (0.06-0.82), P = 0.02 (alcohol abuse), OR: 0.15 (0.04-0.60), P = 0.008 (altered mental state), OR: 0.22 (0.07-0.71), P = 0.01 (temperature < 38 °C), OR: 0.23 (0.07-0.79), P = 0.02 (septic shock), OR: 0.21 (0.06-0.69), P = 0.01 (mechanical ventilation).

Conclusion

Our results suggest that, after susceptibility testing, cefuroxime or aminopenicillins are preferable to benzylpenicillins as definitive therapy for Haemophilus bacteremia.

【 授权许可】

   
2012 Thønnings and Østergaard; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Laupland KB, Schonheyder HC, Ostergaard C, Knudsen JD, Valiquette L, Galbraith J, Kennedy KJ, Gradel KO: Epidemiology of Haemophilus influenzae bacteremia: a multi-national population-based assessment. J Infect 2011, 62:142-148.
• [2]Peltola H, Anttila M, Renkonen OV: Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group [see comments]. Lancet 1989, 1:1281-1287.
• [3]Schaad UB, Suter S, Gianella Borradori A, Pfenninger J, Auckenthaler R, Bernath O, Cheseaux JJ, Wedgwood J: A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990, 322:141-147.
• [4]Westh H, Frimodt-Moller N, Gutschik E, Bangsborg J: Killing curve activity of ciprofloxacin is comparable to synergistic effect of beta-lactam-tobramycin combinations against Haemophilus species endocarditis strains. APMIS 1992, 100:856-860.
• [5]European Committee on Antimicrobial Susceptibility Testing: Benzylpenicillin: Rationale for the clinical breakpoints, version 1.0, 2010. 2011. http://www.eucast.org webcite
• [6]Bamberger DM, Foxworth JW, Bridwell DL, Shain CS, Gerding DN: Extravascular antimicrobial distribution and respective blood and urine concentrations in humans. In Antibiotics in Laboratory Medicine. Fifth Edition edition. Edited by Lorian V. , ; 2005:719-809.
• [7]Mayo JB, McCarthy LR: Antimicrobial susceptibility of Haemophilus parainfluenzae. Antimicrob Agents Chemother 1977, 11:844-847.
• [8]Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR: A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996, 49:1373-1379.
• [9]McVernon J, Trotter CL, Slack MP, Ramsay ME: Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004, 329:655-658.
• [10]Ulanova M, Tsang RS: Invasive Haemophilus influenzae disease: changing epidemiology and host-parasite interactions in the 21st century. Infect Genet Evol 2009, 9:594-605.
• [11]Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN: Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010, 28:4073-4078.
• [12]Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M: Haemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998, 4:229-237.
• [13]Garpenholt O, Hugosson S, Fredlund H, Giesecke J, Olcen P: Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children. Acta Paediatr 2000, 89:471-474.
• [14]Campos J, Hernando M, Roman F, Perez-Vazquez M, Aracil B, Oteo J, Lazaro E, de Abajo F: Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b. J Clin Microbiol 2004, 42:524-529.
• [15]Scheifele DW, Bettinger JA, Halperin SA, Law B, Bortolussi R: Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004–2007. Pediatr Infect Dis J 2008, 27:755-757.
• [16]Peltola H, Aavitsland P, Hansen KG, Jonsdottir KE, Nokleby H, Romanus V: Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999, 179:223-229.
• [17]Farley MM, Stephens DS, Brachman PS, Harvey RC, Smith JD, Wenger JD: Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med 1992, 116:806-812.
• [18]Kostman JR, Sherry BL, Fligner CL, Egaas S, Sheeran P, Baken L, Bauwens JE, Clausen C, Sherer DM, Plorde JJ, et al.: Invasive Haemophilus influenzae infections in older children and adults in Seattle. Clin Infect Dis 1993, 17:389-396.
• [19]Sarangi J, Cartwright K, Stuart J, Brookes S, Morris R, Slack M: Invasive Haemophilus influenzae disease in adults. Epidemiol Infect 2000, 124:441-447.
• [20]Ladhani S, Slack MP, Heath PT, von Gottberg A, Chandra M, Ramsay ME: Invasive Haemophilus influenzae Disease, Europe, 1996–2006. Emerg Infect Dis 2010, 16:455-463.
• [21]Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH: Manual of clinical microbiology. American Society for Microbiology, Washington D.C.; 1999.
• [22]Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140.
• [23]Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, et al.: Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
• [24]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.